Study of TFX06 in Women With Advanced Breast Cancer.
A Phase 1/2 Dose Escalation and Expansion Study of TFX06 tablet Alone in Women with ER Positive, HER2 Negative Advanced Breast Cancer
ER+, HER2- Advanced Breast Cancer|Metastatic Breast Cancer
DRUG: TFX06 tablet
Recommended phase 2 Dose (RP2D), RP2D of TFX06 tablet when administered as monotherapy(PartA), The first 28 days of treatmen|Disease Control Rate, Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumor (RECIST 1.1) (Part B), From baseline to the date of first documentation of progression ,assessed up to 24months
Incidence of Treatment-Emergent Adverse Events (AE) [Safety and Tolerability], AE will be graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0, Up to 30 days after the end of treatment|Electrocardiogram (ECG) changes [Safety and Tolerability], Resting 12-lead ECGs will be obtained from all subjects in order to assess any impact TFX06 may have on the QT interval as assessed by the Fridericia's Correction Formula (QTcF)., Up to 30 days after the end of treatment|Monitoring of Vital signs [Safety and Tolerability], Vital sign will be obtained from all subjects, Up to 30 days after the end of treatment|Monitoring of hematology and blood chemistry [Safety and Tolerability], Hematology and blood chemistry will be obtained from all subjects., Up to 30 days after the end of treatment|Monitoring of coagulation function[Safety and Tolerability], Coagulation function will be obtained from all subjects., Up to 30 days after the end of treatment|Monitoring of urinalysis [Safety and Tolerability], Urinalysis will be obtained from all subjects., Up to 30 days after the end of treatment|Plasma concentrations of TFX06 will be assessed at predefined intervals, Pharmacokinetics of TFX06, Cycle0, Cycle 1(36 days)
This is a phase Ⅰ/Ⅱ, open-label study of TFX06 tablet single agent to assess the safety and tolerability, identify an Maximum Tolerated Dose （MTD）, and/or RP2D, evaluate the pharmacokinetic（PK ）properties and evaluate preliminary anti-tumor activities in women with advanced or metastatic ER-positive, HER2-negative breast cancer.